You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 4,507,234


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,507,234
Title: Conjugate having cytotoxicity and process for the preparation thereof
Abstract:A conjugate having cytotoxicity prepared by covalently binding a serum albumin having cytotoxic substance linked thereto to an immunoglobulin, or its fragment, which is able to bind selectively with a particular antigen of cells to be killed.
Inventor(s): Kato; Yoshinori (Hino, JP), Umemoto; Naoji (Hino, JP), Saito; Masahiko (Saitama, JP), Hara; Takeshi (Hachioji, JP)
Assignee: Teijin Limited (Osaka, JP)
Application Number:06/563,860
Patent Claims:1. A conjugate having cytotoxicity prepared by covalently binding a serum albumin having a cytotoxic substance linked thereto to an immunoglobulin, or its fragment, which is able to selectively bind to a particular antigen of a cell to be killed,

wherein said immunoglobulin or its fragment is bound to said serum albumin by means of at least one sulfur atom, and wherein said serum albumin is linked to said cytoxic substance by an imino group.

2. The conjugate having cytotoxicity according to claim 1, wherein said serum albumin is a human or bovine serum albumin.

3. The conjugate having cytotoxicity according to claim 1, wherein the conjugate is expressed by the following formula (I)

wherein Ab indicates an immunoglobulin or its fragment, Al a serum albumin, and Cy a cytotoxic substance respectively; S.sub.1 and NH indicate a sulfur atom and an imino group in the serum albumin respectively; B.sub.1 indicates a divalent organic group; m indicates an integer 1 to 30 and n an integer 1 to 10 respectively.

4. The conjugate having cytotoxicity according any one of claims 1, 2, or 3, wherein the conjugate is expressed by the following formula (II)

wherein Ab indicates a serum albumin; Cy indicates a cytotoxic substance; S.sub.1 and NH indicate a sulfur atom or an imino group in the serum albumin respectively; m indicates an integer of 1 to 30; n indicates an integer of 1 to 10; S.sub.2 indicates a sulfur atom; B.sub.2 and B.sub.3 indicate divalent organic groups; t.sub.2 and t.sub.3 are identical with or different from each other; being 1 or 1; providing that when t.sub.2 equals 0, S.sub.2 is a sulfur atom arising from the immunoglobulin or its fragment and when t.sub.2 equals 1, S.sub.2 is a sulfur atom introduced by a cross-linking agent.

5. The conjugate having cytotoxicity according to any one of claims 1, 2 or 3, wherein the conjugate is expressed by the following formula (III) ##STR48## wherein Ab indicates an immunoglobulin or its fragment; Al indicates a serum albumin; Cy indicates a cytotoxic substance; S.sub.1 and NH indicate a sulfur atom and an imino group in the serum albumin respectively; m indicates an integer of 1 to 30; n indicates an integer of 1 to 10; and B.sub.4 indicates a divalent organic group.

6. A process for the preparation of a conjugate having cytotoxicity expressed by the following formula (II-1)

wherein Ab indicates an immunoglobulin or its fragment; Al indicates a serum albumin; Cy indicates a cytotoxic substance; S.sub.1 and NH indicate a sulfur atom and an imino group in the serum albumin respectively; m indicates an integer of 1 to 30; n indicates an integer of 1 to 10; S.sub.2 indicates a sulfur atom; B.sub.2 indicates a divalent organic group; and t.sub.2 indicates 0 or 1, providing that when t.sub.2 equals 0, S.sub.2 is a sulfur atom arising from the immunoglobulin or its fragment and when t.sub.2 equals 1, S.sub.2 is a sulfur atom introduced by a cross-linking agent:

characterized by covalently binding a serum albumin expressed by the following formula (V) having a group capable of forming an active disulfide group and having a cytotoxic substance linked thereto

wherein Al indicates a serum albumin; Cy indicates a cytotoxic substance; S.sub.1 and NH indicate a sulfur atom and an imino group in the serum albumin respectively; m indicates an integer of 1 to 30; and X indicates a group which is capable of forming an active disulfide linkage with the neighboring sulfur atom;

with an immunoglobulin or its fragment expressed by the following (IV) having a generated or introduced thiol group

wherein Ab indicates an immunoglobulin or its fragment; S.sub.2 indicates a sulfur atom; B.sub.2 indicates a divalent organic group; t.sub.2 is 0 or 1; and n' is an integer of 1 to 10; providing that when t.sub.2 equals 0, S.sub.2 is a sulfur atom arising from the immunoglobulin or its fragments and when t.sub.2 equals 1, S.sub.2 is a sulfur atom introduced by a cross-linking agent.

7. A process for the preparation of a conjugate having cytotoxicity expressed by the formula (II-1)

wherein Ab indicates an immunoglobulin or its fragment; Al indicates a serum albumin; Cy indicates a cytotoxic substance; S.sub.1 and NH indicate a sulfur atom and an imino group in the serum albumin respectively; m indicates an integer of 1 to 30; n indicates an integer of 1 to 10; S.sub.2 indicates a sulfur atom; B.sub.2 is a divalent organic group; and t.sub.2 is 0 or 1; providing that when t.sub.2 equals 0, S.sub.2 is a sulfur atom arising from the immunoglobulin or its fragment and when t.sub.2 equals 1, S.sub.2 is a sulfur introduced by a cross-linking agent:

characterized by covalently binding a serum albumin expressed by the following formula (VII) having a cytotoxic substance linked thereto

wherein Al represents a serum albumin; Cy represents a cytotoxic substance; S.sub.1 and NH represent a sulfur atom and an imino group in the serum albumin respectively; and m indicates an integer of 1 to 30:

with an immunoglobulin or its fragment expressed by the following formula (VI) having an induced or introduced active disulfide group

wherein Ab indicates an immunoglobulin or its fragment; S.sub.2 indicates a sulfur atom; B.sub.2 indicates a divalent organic group; t.sub.2 is 0 or 1; n' is an integer of 1 to 10; and X represents a group which is capable of forming an active disulfide linkage with the neighboring sulfur atom; providing that when t.sub.2 equals 0, S.sub.2 is a sulfur atom arising from the immunoglobulin or its fragment and when t.sub.2 equals 1, S.sub.2 is a sulfur atom introduced by a cross-linking agent.

8. A process for the preparation of a conjugate having cytotoxicity expressed by the following formula (II-2)

wherein Ab indicates an immunoglobulin or its fragment; Al indicates a serum albumin; Cy indicates a cytotoxic substance; S.sub.1 and NH indicate a sulfur atom and an imino group in the serum albumin respectively; m indicates an integer of 1 to 30; n indicates an integer of 1 to 10; S.sub.2 indicates a sulfur atom; B.sub.2 and B.sub.3 are divalent organic groups; and t.sub.2 is 0 or 1, providing that when t.sub.2 equals 0, S.sub.2 is a sulfur atom arising from the immunoglobulin or its fragment and when t.sub.2 equals 1, S.sub.2 is a sufur atom introduced by a cross-linking agent:

characterized by covalently binding a serum albumin, which has a cytotoxic substance linked thereto, expressed by the formula (VII)

wherein Al indicates a serum albumin; Cy indicates a cytotoxic substance; S.sub.1 and NH indicate a sulfur atom and an imino group in the serum albumin respectively; and m indicates an integer of 1 to 30:

to an immunoglobulin or its fragment, which has a generated or introduced thiol group, expressed by the formula (IV)

wherein Ab indicates an immunoglobulin or its or its fragment; S.sub.2 indicates a sulfur atom; B.sub.2 is a divalent organic group; t.sub.2 is 0 or 1; and n' is an integer of 1 to 10; providing that when t.sub.2 equals 0, S.sub.2 is a sulfur atom arising from the immunoglobulin or its fragment and when t.sub.2 equals 1, S.sub.2 is a sulfur atom introduced by a cross-linking agent:

with the use of a cross-linking agent having two functional groups which are capable of reacting with a thiol group.

9. A process for the preparation of a conjugate having cytotoxicity expressed by formula (III) ##STR49## wherein Ab represents an immunoglobulin or its fragment; Al represents a serum albumin; Cy represents a cytotoxic substance; S.sub.1 and NH represent a sulfur atom and an imino group in the serum albumin respectively; m represents an integer of 1 to 30; n represents an integer of 1 to 10; and B.sub.4 represents a divalent organic group:

characterized by covalently binding a serum albumin, which has a cytotoxic substance linked thereto, expressed by the formula (VII)

wherein Al represents a serum albumin; Cy represents a cytotoxic substance; S.sub.1 and NH represent a sulfur atom and an imino group in the serum albumin respectively; and m represents an integer of 1 to 30:

with an immunoglobulin or its fragment, which has an introduced maleimide group, expressed by the following formula (VIII) ##STR50## wherein Ab represents an immunoglobulin or its fragment; n' represents an integer of 1 to 10; and B.sub.4 represents a divalent organic group.

10. The conjugate having cytotoxicity according to claim 2, wherein the conjugate is expressed by the following formula (I)

wherein Ab indicates an immunoglobulin or its fragment, Al a serum albumin, and Cy a cytotoxic substance respectively; S.sub.1 and NH indicate a sulfur atom and an imino group in the serum albumin respectively; B.sub.1 indicates a divalent organic group; m indicates an integer 1 to 30 and n an integer 1 to 10 respectively.

Details for Patent 4,507,234

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 10/21/1942 ⤷  Try a Trial 2002-12-24
Baxalta Us Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 03/03/1954 ⤷  Try a Trial 2002-12-24
Csl Behring Ag ALBURX albumin (human) Injection 102366 07/23/1976 ⤷  Try a Trial 2002-12-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.